Slide 1: Innovating for the healthcare needs of today and tomorrow
Innovating for the healthcare needs of today and tomorrow 2014 Year-end report presentation 19 February 2015
Slide 2: Our new headquarters
Our new headquarters
Slide 3: Our Vision
Our Vision Defining the universal standard of care for prevention of Healthcare Associated Infections (HAI) together with policy makers, academia and healthcare Policy, laws & regulations Implementation New Surveillance Standards of Care Adequate Prevention treatment 3
Slide 4: The global health scare: Deaths attributable to AMR
The global health scare Deaths attributable to AMR Compared to other major causes of death ”Ten million people at risk if antimicrobial resistance is not tackled” ”The spread of AMR is expected to reduce global GDP by 2 – 3.5 percent” Review on Antimicrobial Resistance (AMR), Tackling drug-resistant
Slide 5: Bactiguard Infection Protection
Targets the most common HAIs Bactiguard Infection Protection ...explaining the rationale behind the products in Occurrence of HAI US (all hospital types) the Bactiguard portfolio Other Urinary tract BIP Foley 17% 32% Surgical site 22% 14% 15% Blood stream BIP ETT Respiratory tract Medical devices, f
Slide 6: Market expansion
Market expansion Increased footprint and market access – a doubling of markets with product deliveries Bactiguard presence Countries with distribution agreements Direct sales Bard territory* Production facility Portfolio roll-out Markets Markets Markets with with product approval deliveries 2011 17
Slide 7: Highlights in the fourth quarter
Highlights in the fourth quarter • Weaker performance compared to 2013 • Stable license business with C.R Bard • Lower sales and deliveries of BIP portfolio • Negotiations continuing in Iraq • Senior sales staff for Sweden and South East Asia recruited • Developing European strategy • Preparations f
Slide 8: Financial overview: Highlights
Financial overview Highlights Fourth quarter (Oct-Dec 2014) • Revenues of MSEK 25.1, minus 48% compared to 2013 (major delivery to Iraq in Q4 2013 affects comparison) • EBITDA of MSEK -3.9 (25.2), a margin of -16% (53%) Full year (Jan-Dec 2014) • Revenues of MSEK 118.9, minus 9% compared to 2013 • E
Slide 9: Supplied products
Financial overview Supplied products • 8,000 BIP products supplied in Q4 2014 compared to 105,000 during Q4 2013. • For the full year 2014, 79,000 BIP products were supplied compared to approx. 190,000 for the full year 2013. 9
Slide 10: Strengthening of Sales & Marketing organization
Strengthening of Sales & Marketing organization 30 25 20 12 15 Consultants* 6 Employees 10 11 12 5 7 0 2013 Dec 2015 Jan 2015 planned * Primarily consultants in local markets 10
Slide 11: Revenue streams
Financial overview Revenue streams Three revenue streams in the income statement License BIP portfolio Bard license deal BIP Foley BIP ETT BIP CVC (sales since 1995) 1 2 3 License Territorial fee BIP revenue From a product perspective Bactiguard has two lines of business; Licenses and the BIP portfo
Slide 12: Income distribution
Financial overview Income distribution Oct-Dec Full year Full year Full year 2014 2014 2013 2013 License revenues 20,2 89,8 82,7 63,1% Territorial fees 0,1 17,1 7,2 5,5% BIP products 0,1 2,2 36,8 28,1% Other revenue 4,7 9,8 4,4 3,3% Total Revenues 25,1 118,9 131,1 13109,9% 12
Slide 13: Key figures
Financial overview Key figures Key figures Oct-Dec Oct-Dec Full year Full year • EBITDA (Q4) MSEK -3.9 2014 2013 2014 2013 Revenues, SEKm 25,1 47,9 118,9 131,1 • EBITDA adjusted (Full year EBITDA, SEKm -3,9 25,2 10,3 40,0 2014) MSEK 13.3, 11% EBITDA margin, % -16% 53% 9% 31% margin EBITDA*, SEKm -3,
Slide 14: Sensitivity analysis and cash position
Cash flow Sensitivity analysis and cash position Worst case scenario based on Q4. Only License fees, no BIP revenues or Territorial fees. Operational costs at a level scheduled for expansion. MSEK Q4 Annualised EBITDA -3,9 Non-recurring items 2,0 Extra costs premises 1,3 Adjusted EBITDA -0,6 -2,3
Slide 15: Financial flexibility and strength
Financial overview Financial flexibility and strength Q2 Share issue of MSEK 20 in April Set off issue of MSEK 222.5 in June Share issue of MSEK 240 in connection with IPO Q3 • Repurchase of bonds, nominal value MSEK 18.5 Q4 • Repurchase of bonds, nominal value MSEK 20.5 • Equity ratio of 64 %
Slide 16: Investing for the future
Investing for the future • Healthcare associated infections and multiresistant bacteria - two of the greatest challenges of our time • Prevention is key - Bactiguard has an efficient, safe and well proven solution for infection control • 2014 focused on building the platform for future business expa
Slide 17: Niels Christiansen new CEO
Niels Christiansen new CEO Niels Christiansen, appointed new CEO from March 16. Extensive management experience from various positions in the medical device, life science and energy sectors, most recently as the CEO of HemoCue AB. More than 20 years in various CEO functions and managerial positions
Slide 18: Find more information
Find more information Please visit our website www.bactiguard.com For questions and additional information, please contact: Johan Rugfelt, CEO: +46 8 440 58 76 johan.rugfelt@bactiguard.se Fredrik Järrsten, CFO: +46 725 500 089 fredrik.jarrsten@bactiguard.se Cecilia Edström, Director of Sales, Market